Evaluating the Utility of Complete Blood Count-Derived Inflammatory Indices for Predicting Clinical Outcomes in Earthquake-Related Crush Injuries: The 2023 Turkey-Syria Earthquake
Disaster Medicine and Public Health Preparedness · 2025 · 19
DOI: 10.1017/dmp.2025.10199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disaster Medicine and Public Health Preparedness, online erschienen am 06.10.2025. Verfasst von Fatma Zehra Agan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, https://ror.org/057qfs197Harran University Faculty of Medicine, Sanliurfa, Turkey. Hauptthemen laut MEDLINE: Earthquakes, Crush Syndrome, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Earthquakes cause significant mortality and morbidity, particularly through crush injuries and their complications. This study aimed to evaluate whether systemic immune inflammation index (SII) and Pan-immune inflammatory values (PIV) obtained from complete blood count parameters can predict intensive care needs, dialysis requirements, and mortality in patients with crush injuries following earthquake.
Methods
We retrospectively analyzed data from 76 patients with crush injuries admitted to a university hospital following the earthquake. Blood samples were collected upon admission. SII and PIV were calculated and compared with conventional laboratory markers for their ability to predict clinical outcomes.
Results
Intensive care unit (ICU) admission was required in 40.8% of patients, and 21.1% required dialysis. In ROC analysis, an SII value above 1372 predicted ICU admission with 67.7% sensitivity and 66.7% specificity ( P < .001), while an SII value above 1735 predicted dialysis requirement with 75.0% sensitivity and 73.3% specificity ( P < .001). Similarly, a PIV value above 1345 predicted ICU admission with 74.2% sensitivity and 73.3% specificity ( P < .001), and a value above 1906 predicted dialysis requirement with 81.3% sensitivity and 78.3% specificity ( P < .001).
Conclusions
Complete blood count-derived inflammatory markers may serve as accessible, early indicators to complement clinical assessment for resource allocation following earthquake-related crush injuries, particularly in resource-limited disaster settings. These tools may aid in patient triage and care planning when comprehensive laboratory testing is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, https://ror.org/057qfs197Harran University Faculty of Medicine, Sanliurfa, Turkey.
- Department of Emergency Medicine, Istanbul Research and Training Hospital, University of Health Sciences, Istanbul, Turkey.
- Harran University Faculty of Medicine, Sanliurfa, Turkey.
ORCID-Profile: Fatma Zehra Agan, Cigdem Cindolu, Derya Abuska, Abdelrahman Abouelsoud
Zitieren
APA
Agan, F. Z., Cindolu, C., Abuska, D., & Abouelsoud, A. (2025). Evaluating the Utility of Complete Blood Count-Derived Inflammatory Indices for Predicting Clinical Outcomes in Earthquake-Related Crush Injuries: The 2023 Turkey-Syria Earthquake. Disaster Medicine and Public Health Preparedness, 19. https://doi.org/10.1017/dmp.2025.10199
Vancouver
Agan FZ, Cindolu C, Abuska D, Abouelsoud A. Evaluating the Utility of Complete Blood Count-Derived Inflammatory Indices for Predicting Clinical Outcomes in Earthquake-Related Crush Injuries: The 2023 Turkey-Syria Earthquake. Disaster Medicine and Public Health Preparedness. 2025;19. doi:10.1017/dmp.2025.10199
BibTeX
@article{Agan2025,
author = {Agan, Fatma Zehra and Cindolu, Cigdem and Abuska, Derya and Abouelsoud, Abdelrahman},
title = {Evaluating the Utility of Complete Blood Count-Derived Inflammatory Indices for Predicting Clinical Outcomes in Earthquake-Related Crush Injuries: The 2023 Turkey-Syria Earthquake},
journal = {Disaster Medicine and Public Health Preparedness},
year = {2025},
volume = {19},
doi = {10.1017/dmp.2025.10199}
}
EUVIMED